Navigation Links
Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/10/2013

ed by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended March 31, 2013, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

 

 

 INOVIO PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2013December 31,
2012(Unaudited)ASSETSCurrent assets:Cash and cash equivalents

$

20,086,799$

5,646,021Short-term investments

7,978,3458,034,001Accounts receivable

1,029,158830,433Accounts receivable from affiliated entity

43,53736,234Prepaid expenses and other current assets

283,044471,328Prepaid expenses and other current assets from affiliate
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
2. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
3. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
4. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
5. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
6. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
9. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
10. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
11. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... COPENHAGEN, Denmark , Sept. 16, 2014 /PRNewswire/ ... its innovative TransCon technology to address significant unmet ... its ongoing Phase 2 pediatric study to evaluate ... hormone deficiency, or GHD.  The full interim results ... of the GRS and IGF Society, being held ...
(Date:9/15/2014)... drives classical phase transitionsthink solid, liquid, and ... the temperature drops. If phase transitions occur ... mechanics reigns, subtle fluctuations can dramatically transform ... U.S. Department of Energy,s Brookhaven National Laboratory ... frigid landscape of absolute zero to isolate ...
(Date:9/15/2014)... have developed a technique for controlling the surface tension ... the door to a new generation of reconfigurable electronic ... the fact that the oxide "skin" of the metal ... as a surfactant, lowering the surface tension between the ... a liquid metal alloy of gallium and indium. In ...
(Date:9/15/2014)... IRVINE, Calif. , Sept. 15, 2014 /PRNewswire/ ... a new viral transport solution for safe ambient ... prior to molecular testing. Importantly, the infectivity of agents ... solution while maintaining the integrity of the viral ... news of the recent Ebola epidemic in ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3Researchers control surface tension to manipulate liquid metals 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3
... programs for the University of Wisconsin-Madison, is part information technologist, ... Part II of this interview. In Part I , ... (below), he addresses creating a culture of innovation and finding ... featured speaker at the Fusion 2007 CEO-CIO Symposium . ...
... In a move that could bring additional investment partners to ... an office in Ann Arbor, Mich. after receiving money from ... which recently moved into a larger space in the MGE ... of three venture firms selected to receive funding through a ...
... - Oskar Anderson, chief information officer for the Wisconsin ... succeed Matt Miszewski as administrator of the state Division ... this week, will join the Department of Administration ... His appointment was confirmed this morning in an e-mail to ...
Cached Biology Technology:Venture Investors to open Michigan office 2Oskar Anderson to succeed Miszewski as head of state technology division 2
(Date:9/16/2014)... "molecular brakes" that time the generation of important cells ... cells" translate sound waves into electrical signals that are ... If the arrangement of the cells is disordered, hearing ... will be published in The Journal of Neuroscience ... Hey2 act as brakes to prevent hair cell generation ...
(Date:9/16/2014)... the dinosaurs 66 million years ago decimated the evergreens ... than their deciduous peers, according to a study led ... journal PLOS Biology . , Applying biomechanical ... leaves of angiosperms flowering plants excluding conifers ... of a diverse plant community thriving during a 2.2 ...
(Date:9/16/2014)... returned to Spain culminating the around the world of ... of how the global ocean works and what is ... the atmosphere is not limited to coastal areas, but ... planet, and it is already affecting the ocean ecosystem. ... CSIC Residence for Researchers in Barcelona, in a congress ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3
... research team from Rollins College in Florida and the University ... the coral-killing pathogen that causes white pox disease of Caribbean ... elkhorn coral was listed for protection under the United States ... disease. The team,s findings have just been published in the ...
... A recent study demonstrated increased rates of celiac disease ... in the May-June 2011 issue of The Journal ... patients presenting with infertility. Each participant underwent serologic ... testing. The 4 patients who had positive serum ...
... , Cincinnati, (OH) - The International Rett Syndrome Foundation ... to support eight cutting-edge projects that aim to accelerate ... IRSF is the world,s largest private source of funding ... 1998, IRSF has cumulatively funded over $24M in high ...
Cached Biology News:Human pathogen killing corals in the Florida Keys 2Human pathogen killing corals in the Florida Keys 3IRSF awards over $650,000 for Translational Rett Syndrome research 2
... Our Accumix standard is a new tuning ... electrospray ionization mass spectrometry. Accumix is ... mass range coverage for both tuning and ... and LTQ-MS) and Fourier transform mass spectrometers. ...
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Biology Products: